Your Messages Inbox
Your Article Summary
See Latest ArticlesWatson Pharmaceuticals Receives FDA Final Approval for Generic Mircette
Watson Pharmaceuticals, 01/06/09
Watson Pharmaceuticals, Inc., a leader in generic and specialty branded pharmaceuticals, announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for desogestrel/ethinyl estradiol and ethinyl estradiol tablets, 0.15 mg/0.02 mg and 0.01 mg and placebo tablets (28- day regimen). Desogestrel/ethinyl estradiol and ethinyl estradiol tablets, 0.15 mg/0.02 mg and 0.01 mg and placebo tablets (28- day regimen) are the generic equivalent to Duramed Pharmaceuticals' Mircette low-dose monthly oral contraceptive product, which is indicated for prevention of pregnancy.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
Article Search
Sponsor